Safety, PK, and Preliminary Efficacy of MBRC-101 in Advanced Refractory Solid Tumors | ClinicalTrials HQ

Ask about research services

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Safety, PK, and Preliminary Efficacy of MBRC-101 in Advanced Refractory Solid Tumors	cancer, neoplasm	Recruiting	Phase 1 / Phase 2	2026-03-02		NCT06014658

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
MBrace Therapeutics	2

17 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
Carolina BioOncology Institute	Huntersville	United States	22
Columbia University Irving Medical Center	New York	United States	234
Comprehensive Cancer Center of Nevada	Las Vegas	United States	2
Fox Chase Cancer Center	Philadelphia	United States	259
Horizon Oncology Research	Lafayette	United States	1
Karmanos Cancer Institute	Detroit	United States	153
Medical University of South Carolina (MUSC)	Charleston	United States	34
NEXT Oncology	Fairfax	United States	31
NEXT Oncology	Irving	United States	11
NEXT Oncology	Austin	United States	8
PRISMA Health, Institute for Translational Oncology	Greenville	United States	1
Rutgers Cancer Institute of New Jersey	New Brunswick	United States	223
UCSF Helen Diller Family Comprehensive Cancer Center	San Francisco	United States	22
University of Chicago Medical Center	Chicago	United States	152
University of Colorado, Anschutz Cancer Pavilion (ACP(	Aurora	United States	1
University of Pennsylvania, Abramson Cancer Center	Philadelphia	United States	1
Winship Cancer Institute, Emory University	Atlanta	United States	47